Proteomics-based analysis revealed that EA-2 exerts its effects by modulating the JAK-STAT, PI3K-Akt, and PPAR signaling pathways, as well as lipid metabolism-related pathways, thereby synergistically suppressing proliferation and promoting apoptosis in breast cancer cells. Here, PPARA is linked to breast carcinoma.